---
category: news
title: "Eli Lilly, spurred by AI analysis, starts phase 3 study of arthritis med Olumiant in COVID-19"
excerpt: "Eli Lilly has kicked off a phase 3 clinical trial testing whether Olumiant can cut the rate of death or the need for ventilation or other oxygen support in 400 hospitalized COVID-19 patients. The company-sponsored trial follows an NIH study combining the JAK inhibitor with Gilead's remdesivir."
publishedDateTime: 2020-06-15T15:21:00Z
webUrl: "https://www.fiercepharma.com/pharma/lilly-starts-testing-arthritis-med-olumiant-covid-19-alongside-antibody-works"
type: article
quality: 26
heat: 26
published: false

provider:
  name: FiercePharma
  domain: fiercepharma.com

topics:
  - AI

images:
  - url: "https://qtxasset.com/fiercepharma/1592232252/olumiant.png/olumiant.png?9LdbplxSLG31MDzkVEsTxs5LhSm8bwtZ"
    width: 1100
    height: 800
    isCached: true
    title: "Eli Lilly, spurred by AI analysis, starts phase 3 study of arthritis med Olumiant in COVID-19"

secured: "CuuKMEWrUHOccfsTf6AMl8YSNT7loR/tzzSY0WT/hl19ZNyvFMSoOhGh8lqFnGsWuLSNfVInx7tCoaD/p338PbsfYbL/BwcvMU45L37EPjv/0BcTv3MsWzC2FtqrpFKqSiVCjnHUbx5jmBSlDDcnJCxlpSrdHveJtgjR22mpSJ5/ng8sn4bH1Pd7ZwEAvTWUDpzLS69PVAEpqL8RYCHingt406vXdnCUA+Wu0cO9G0piBfbJEm2yQUQK+lodNdOGC2txVy4D6bDZ3PCvb1OehwwEojAvh2JkVzL2WQ15aa4tMb14hGG0RKxU1IdQ95EDt+hfJu7BTvUwMeQtJzDD/Q==;msoVaaQY4Itl9v3M4JDD3Q=="
---

